These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16722819)

  • 1. Inhibition of RANKL: a new approach to the treatment of osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2006 Jun; 7(8):1097-100. PubMed ID: 16722819
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab: new horizons in the treatment of osteoporosis.
    Wilton JM
    Nurs Womens Health; 2011; 15(3):249-52. PubMed ID: 21672176
    [No Abstract]   [Full Text] [Related]  

  • 5. [Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
    Törring O
    Lakartidningen; 2010 Mar 3-9; 107(9):574-5. PubMed ID: 20387753
    [No Abstract]   [Full Text] [Related]  

  • 6. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 7. The RANKL pathway and denosumab.
    Dore RK
    Rheum Dis Clin North Am; 2011 Aug; 37(3):433-52, vi-vii. PubMed ID: 22023901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab for the treatment of postmenopausal osteoporosis.
    Lewiecki EM
    Womens Health (Lond); 2009 Jan; 5(1):15-22. PubMed ID: 19274891
    [No Abstract]   [Full Text] [Related]  

  • 9. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149
    [No Abstract]   [Full Text] [Related]  

  • 10. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoporosis treatment by anti-RANKL antibody].
    Sugimoto T
    Clin Calcium; 2011 Aug; 21(8):1209-15. PubMed ID: 21814027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
    Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
    N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.
    Anastasilakis AD; Toulis KA; Goulis DG; Polyzos SA; Delaroudis S; Giomisi A; Terpos E
    Horm Metab Res; 2009 Oct; 41(10):721-9. PubMed ID: 19536731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANK ligand inhibition with denosumab for the management of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on denosumab in postmenopausal osteoporosis.
    Moen MD; Keam SJ
    BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab update.
    Lewiecki EM
    Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.